1-20 of 49
Authors: D Busquets
Save search
Sort by
Journal Article

DOP038 Impact of prenatal and breastfeeding exposure to biologic drugs on the first-year anthropometric development of infants born to mothers with inflammatory bowel disease from DUMBO registry of GETECCU

PDF
L Palomino and others
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i152–i154, https://doi.org/10.1093/ecco-jcc/jjae190.0077
Published: 22 January 2025
Journal Article

P0226 Postoperative recurrence after a definitive ostomy in Crohn's disease. A nationwide retrospective series from the Eneida registry

PDF
M Calafat Sard and others
Journal of Crohn's and Colitis, Volume 19, Issue Supplement_1, January 2025, Pages i641–i642, https://doi.org/10.1093/ecco-jcc/jjae190.0400
Published: 22 January 2025
Journal Article

P649 Long-term follow-up of the PROTDILAT study; LONG-PROTDILAT Prospective multicenter randomized comparative study of endoscopic treatment of strictures in Crohn's disease (CD): self-expandable metal stent (SEMS) vs endoscopic balloon dilatation (EBD)

PDF
P Ruiz Ramírez and others
Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Page i1236, https://doi.org/10.1093/ecco-jcc/jjad212.0779
Published: 24 January 2024
Journal Article

P676 Unveiling the impact on in utero exposure to biologic treatments for inflammatory bowel disease (IBD) on children's psychomotor development: Insights from the DUMBO registry of GETECCU

PDF
L M Palomino Pérez and others
Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Pages i1282–i1284, https://doi.org/10.1093/ecco-jcc/jjad212.0806
Published: 24 January 2024
Journal Article

P844 Frequency and effectiveness of dose de-escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDA

PDF
C Rubín De Célix and others
Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Pages i1567–i1569, https://doi.org/10.1093/ecco-jcc/jjad212.0974
Published: 24 January 2024
Journal Article

P1211 A faecal microbial signature, in combination with faecal calprotectin, to optimise endoscopic activity monitoring in Crohn’s Disease

PDF
S Taboada-López and others
Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Page i2155, https://doi.org/10.1093/ecco-jcc/jjad212.1341
Published: 24 January 2024
Journal Article

P817 Incidence and risk factors of infection in patients with inflammatory bowel disease: longitudinal prospective INFEII registry of GETECCU

PDF
Y Zabana and others
Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Pages i1518–i1520, https://doi.org/10.1093/ecco-jcc/jjad212.0947
Published: 24 January 2024
Journal Article

DOP80 Prevalence and factors associated with Inflammatory Bowel Disease (IBD) activity during pregnancy: updated data from the DUMBO Registry

PDF
M Chaparro and others
Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Pages i222–i225, https://doi.org/10.1093/ecco-jcc/jjad212.0120
Published: 24 January 2024
Journal Article

DOP75 Frequency and effectiveness of dose escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDA

PDF
C Rubín De Célix and others
Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Pages i211–i213, https://doi.org/10.1093/ecco-jcc/jjad212.0115
Published: 24 January 2024
Journal Article

P655 The ileorectal anastomosis after a total colectomy is a feasible and valid surgical alternative in the treatment of inflammatory bowel disease

PDF
I Tapiolas and others
Journal of Crohn's and Colitis, Volume 18, Issue Supplement_1, January 2024, Page i1249, https://doi.org/10.1093/ecco-jcc/jjad212.0785
Published: 24 January 2024
Journal Article

OP37 Is the withdrawal of anti-tumour necrosis factor in inflammatory bowel disease patients in remission feasible without increasing the risk of relapse? Results from the randomised clinical trial of GETECCU (EXIT)

PDF
M Chaparro and others
Journal of Crohn's and Colitis, Volume 17, Issue Supplement_1, February 2023, Pages i50–i54, https://doi.org/10.1093/ecco-jcc/jjac190.0037
Published: 30 January 2023
Journal Article

OP23 Asymptomatic inflammatory bowel disease diagnosed during the colorectal cancer population screening in Catalonia

PDF
E Brunet and others
Journal of Crohn's and Colitis, Volume 17, Issue Supplement_1, February 2023, Pages i31–i32, https://doi.org/10.1093/ecco-jcc/jjac190.0023
Published: 30 January 2023
Journal Article

P634 Ustekinumab and vedolizumab as first-line biological therapy for inflammatory bowel disease. A multicenter study based on the ENEIDA registry.

PDF
M Calafat Sard and others
Journal of Crohn's and Colitis, Volume 17, Issue Supplement_1, February 2023, Pages i766–i767, https://doi.org/10.1093/ecco-jcc/jjac190.0764
Published: 30 January 2023
Journal Article

P625 Randomized controlled trial on the effect of megaboluses of intravenous corticosteroids added to oral corticosteroids in the treatment of moderately active ulcerative colitis

PDF
J Llaó and others
Journal of Crohn's and Colitis, Volume 17, Issue Supplement_1, February 2023, Pages i755–i756, https://doi.org/10.1093/ecco-jcc/jjac190.0755
Published: 30 January 2023
Journal Article

P371 The addition of intravenous, high dose, bolus of methyl-prednisolone increases the early clinical response to oral corticosteroids in moderately active ulcerative colitis. Preliminary results of a prospective, controlled, multicentre, randomised, open-label study

PDF
E Domènech Moral PhD and others
Journal of Crohn's and Colitis, Volume 16, Issue Supplement_1, January 2022, Page i374, https://doi.org/10.1093/ecco-jcc/jjab232.498
Published: 21 January 2022
Journal Article

DOP32 Long-term outcomes of enterocutaneous fistula complicating Crohn’s Disease: The ECUFIT study from GETECCU

PDF
I Rodríguez-Lago and others
Journal of Crohn's and Colitis, Volume 15, Issue Supplement_1, May 2021, Pages S070–S071, https://doi.org/10.1093/ecco-jcc/jjab073.071
Published: 27 May 2021
Journal Article

P476 Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry

PDF
M Chaparro and others
Journal of Crohn's and Colitis, Volume 15, Issue Supplement_1, May 2021, Pages S465–S466, https://doi.org/10.1093/ecco-jcc/jjab076.599
Published: 27 May 2021
Journal Article

P687 Development of a panel of microbial markers to distinguish transient from pathological dysbiosis

PDF
L Oliver and others
Journal of Crohn's and Colitis, Volume 15, Issue Supplement_1, May 2021, Page S606, https://doi.org/10.1093/ecco-jcc/jjab076.807
Published: 27 May 2021
Journal Article

DOP40 Comorbidities and epidemiological risk factor but not immunosuppressive therapies increase the risk of COVID-19 in Inflammatory Bowel Disease (IBD): An ENEIDA-based, case-control study

PDF
Y Zabana Abdo and others
Journal of Crohn's and Colitis, Volume 15, Issue Supplement_1, May 2021, Pages S078–S079, https://doi.org/10.1093/ecco-jcc/jjab073.079
Published: 27 May 2021
Journal Article

P509 Influence of concomitant immunosuppresives in retention rate in Crohn′s Disease patients under ustekinumab in the SUSTAIN Study

PDF
M Chaparro and others
Journal of Crohn's and Colitis, Volume 15, Issue Supplement_1, May 2021, Pages S489–S490, https://doi.org/10.1093/ecco-jcc/jjab076.631
Published: 27 May 2021